Anisocoria as a side effect of paclitaxel treatment

Česká verze

Authors: J. Halámková ¹; D. Adámková Krákorová ¹; R. Demlová ^2,3
Authors place of work: Klinika komplexní onkologické péče LF MU a MOÚ, Brno ¹; Farmakologický ústav, LF MU Brno ²; Oddělení klinického hodnocení, MOÚ Brno ³
Published in the journal: Klin Onkol 2021; 34(4): 306-308
Category: Kazuistika
doi: https://doi.org/10.48095/ccko2021306

Summary

Background: Paclitaxel is one of the most common cytostatics used in oncology; it is part of the therapeutic protocols of many malignancies. One of its most common side effects is peripheral neuropathy. This symptomatology often leads to a reduction in the dose intensity of chemotherapeutic drugs or to early discontinuation of the treatment. Case: In our case report, we describe a rare case of paclitaxel-induced anisocoria in a young woman with breast cancer. Conclusion: Ocular side effects related to taxanes are rare, with an estimated frequency of about 1%. In addition to relatively frequent obstruction of the nasolacrimal duct, the cystoid macular edema or ischemic retinopathy have been reported. However, in most cases paclitaxel-induced ocular side effects, there is no need to reduce or discontinue therapy. However, the collaboration of an oncologist with an experienced and trained ophthalmologist is essential.

Keywords:

anisocoria – paclitaxel – chemotherapy-induced polyneuropathy – CIPN

Zdroje

1. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014; 25 (18): 2677–2681. doi: 10.1091/mbc.E14-04-0916.

2. Reyes-Gibby CC, Morrow PK, Buzdar A et al. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009; 10 (11): 1146–1150. doi: 10.1016/j.jpain.2009.04.006.

3. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155 (12): 2461–2470. doi: 10.1016/j.pain.2014.09.020.

4. Martinez JW, Sanchez-Naranjo JC, Londono-De Los Rios PA et al. Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia. Rev Neurol 2019; 69 (3): 94–98. doi: 10.33588/rn.6903.2019035.

5. Zajączkowska R, Kocot-Kępska M, Leppert W et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019; 20 (6): 1451. doi: 10.3390/ijms20061451.

6. SPC Taxol. [online]. Dostupné z: https: //www.sukl.cz/modules/medication/detail.php?code=0076204 &tab=texts.

7. Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of taxanes: the Mayo Clinic experience. Eur J Ophthalmol 2020. [In press]. doi: 10.1177/1120672120969045.

8. Tanaka Y, Bando H, Hara H et al. Cystoid macular edema induced by nab-paclitaxel. Breast Cancer 2015; 22 (3): 324–326. doi: 10.1007/s12282-012-0373-y.

9. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126 : 1605–1606. doi: 10.1001/archopht.126.11.1605.

10. Das A, Ranjan R, Shah PK et al. Paclitaxel -⁠ and/or cyclophosphamide-induced severe 10. ischaemic retinopathy. Clin Exp Ophthalmol 2020; 48 (8): 1113–1115. doi: 10.1111/ceo.13854.